{"created":"2025-02-23T06:38:03.232432+00:00","id":2013600,"links":{},"metadata":{"_buckets":{"deposit":"3c78f0e7-c691-4353-8872-75fc9021929a"},"_deposit":{"created_by":41,"id":"2013600","owners":[41],"pid":{"revision_id":0,"type":"depid","value":"2013600"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02013600","sets":["1727147343679:1730442224523:1730442266291"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Dose-Finding Study of Anti-CD25 Antibody for Targeting Regulatory T Cells in Locoregional Immunotherapy of Malignant Effusion","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Okawaki, Makoto","creatorNameLang":"en"}],"familyNames":[{"familyName":"Okawaki","familyNameLang":"en"}],"givenNames":[{"givenName":"Makoto","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamaguchi, Yoshiyuki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Yamaguchi","familyNameLang":"en"}],"givenNames":[{"givenName":"Yoshiyuki","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okita, Riki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Okita","familyNameLang":"en"}],"givenNames":[{"givenName":"Riki","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ohara, Masahiro","creatorNameLang":"en"}],"familyNames":[{"familyName":"Ohara","familyNameLang":"en"}],"givenNames":[{"givenName":"Masahiro","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okada, Morihito","creatorNameLang":"en"}],"familyNames":[{"familyName":"Okada","familyNameLang":"en"}],"givenNames":[{"givenName":"Morihito","givenNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"(c) Hiroshima University Medical Press."}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Regulatory T cells","subitem_subject_scheme":"Other"},{"subitem_subject":"CD25","subitem_subject_scheme":"Other"},{"subitem_subject":"Basiliximab","subitem_subject_scheme":"Other"},{"subitem_subject":"Malignant effusion","subitem_subject_scheme":"Other"},{"subitem_subject":"OK-432","subitem_subject_scheme":"Other"},{"subitem_subject":"490","subitem_subject_scheme":"NDC"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Effects of low-dose anti-CD25 antibody on targeting regulatory T (Treg) cells in vitro and in vivo were investigated. Human-mouse chimeric anti-CD25 monoclonal antibody basiliximab was administered into the effusion cavity, followed by locoregional immunotherapy using OK-432 on day 7. Peripheral blood mononuclear cells and effusion lymphocytes (ELs) were collected before and after the basiliximab administration and subjected to further investigations. Surface phenotypes, IFN-y production, cytotoxic activity and foxp3 expression of ELs were assessed by flow cytometry, ELISA, 51Cr-releasing assay, and RT-PCR analysis, respectively. We observed that a low concentration of 0.01 μg/ml basiliximab effectively targeted CD4+CD25bri Treg cells while preserving CD4+CD25tlim activated T cells in vitro. This concentration of basiliximab significantly augmented interferon (IFN)- y production of ELs when interleukin (IL)-2 was added on day 0 or on day 1 after basiliximab. In the clinical study, intracavitary administration of basiliximab on day 0 followed by OK-432 on day 7 was as safe, well-tolerated, and effective as using OK-432 alone, and a low-dose of 0.002-0.005 mg/kg basiliximab could target CD4+CD25bri cells for at least 3 days while relatively preserving CD4 +CD25tlim cells. Foxp3 expression of ELs was not changed definitely by the intracavitary basiliximab. These results suggest that low-dose basiliximab can target Treg cells in vitro and in vivo, and subsequently augment the activation of ELs. Locoregional immunotherapy of malignant effusion using the Treg cell-conditioning regimen with low-dose basiliximab followed by OK-432 administration on day 0 or on day 1 should be evaluated for clinical efficacy in the next phase II trial.","subitem_description_language":"en"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Hiroshima University Medical Press"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0018-2052","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AA00664312","subitem_source_identifier_type":"NCID"}]},"item_1617187024783":{"attribute_name":"開始ページ","attribute_value_mlt":[{"subitem_start_page":"37"}]},"item_1617187056579":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"46","bibliographicPageStart":"37","bibliographicVolumeNumber":"57","bibliographic_titles":[{"bibliographic_title":"Hiroshima Journal of Medical Sciences"},{"bibliographic_title":"Hiroshima Journal of Medical Sciences"}]}]},"item_1617258105262":{"attribute_name":"item_1617258105262","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-03-18"}],"displaytype":"simple","filename":"HiroshimaJMedSci_57_37.pdf","filesize":[{"value":"2.4 MB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2013600/files/HiroshimaJMedSci_57_37.pdf"},"version_id":"d7eed509-0511-4e90-a515-456adca29d9b"}]},"item_1732771732025":{"attribute_name":"旧ID","attribute_value":"34950"},"item_title":"Dose-Finding Study of Anti-CD25 Antibody for Targeting Regulatory T Cells in Locoregional Immunotherapy of Malignant Effusion","item_type_id":"40003","owner":"41","path":["1730442266291"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-03-18"},"publish_date":"2023-03-18","publish_status":"0","recid":"2013600","relation_version_is_last":true,"title":["Dose-Finding Study of Anti-CD25 Antibody for Targeting Regulatory T Cells in Locoregional Immunotherapy of Malignant Effusion"],"weko_creator_id":"41","weko_shared_id":-1},"updated":"2025-06-02T03:22:13.511422+00:00"}